Jay Blankenship M.D. Joins Zylö as Vice President of Business Development

Michael Rabin shifts to Vice President of Strategy

GREENVILLE, SC, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced Jay Blankenship M.D. has joined its executive team as vice president of business development. Michael Rabin, formerly vice president of business development and strategy assumes the role of vice president of strategy.

Dr. Blankenship is a board-certified emergency physician with experience as an entrepreneur in several healthcare startups. He trained at the University of Utah completing both a residency in emergency medicine as well as a fellowship in emergency medical services (EMS). He has administrative experience in the medical direction of county EMS systems, hospital transport systems, and aeromedical flight systems. Most recently, he served as the Chair of Emergency Services at Bon Secours St. Francis Health System in Greenville, SC.

Jay previously served as the Medical Director of Lucidity Direct, a start-up technology platform that connects physicians seeking part-time or temporary work with medical practices looking to fill short-term staffing needs. He has also been involved in product development at Bard Access Systems, helping develop an innovative vascular access device. While at the University of Utah, he served as an Associate at the Lassonde New Venture Development Center and Technology Commercialization Office, evaluating novel biotechnologies focusing primarily on early-stage business development, IP, and market analysis.

Dr. Blankenship earned a B.A. in economics from University of Virginia, an M.D. from the University of South Alabama, and an M.B.A. from UNC Chapel Hill.

Scott Pancoast, founder and chief executive officer of Zylö, commented, “We are thrilled to welcome Jay to the Zylö team. He brings a broad understanding of medicine, deep insights into wellness, and strong leadership instincts. And we are fortunate to have Michael on board to assure a smooth transition as he starts shifting his focus towards Zylö’s strategic direction.”

About Zylö Therapeutics: Zylö has developed a disruptive topical delivery system that extends the duration-of-effect, improves the solubility/targeting, and/or enhances the product performance of many therapeutic agents. Notably, the Z-pod^™ technology platform has enabled the Patchless Patch^™ concept and, further, has successfully harnessed the therapeutic potential of nitric oxide, one of the most powerful—and short-lived—biomolecules produced by our bodies. For more details please visit our web site, www.zylotherapeutics.com and follow us on Twitter (@ZyloTherapies).